TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3777901

Group type: EXPERIMENTAL
Intervention: Low-dose ticarcillin (50 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-dose ticarcillin (80 mg/kg)
Number of subjects: 8
Study: 30327982

Group type: EXPERIMENTAL
Intervention: Intraspace group (IS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular group (IM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study: 26910660

Group type: EXPERIMENTAL
Intervention: Neuramis Deep Lidocaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Perlane-L
Number of subjects: 58
Study: 24927436

Group type: EXPERIMENTAL
Intervention: Probiotics administered from the day enteral feeding began
Number of subjects: 257

Group type: COMPARATOR
Intervention: Conventional treatment without probiotics
Number of subjects: 257
Study: 22956296

Group type: EXPERIMENTAL
Intervention: Healthy lifestyles intervention (Year 1: targeted home visits; Year 2: monthly newsletters and group meetings)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (curricula materials during Year 1; monthly newsletters during Year 2)
Number of subjects: 120
Study: 20181255

Group type: EXPERIMENTAL
Intervention: Brief intervention (2 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 19005398

Group type: EXPERIMENTAL
Intervention: Sirolimus plus Tacrolimus (SRL+TAC)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Sirolimus plus Cyclosporine (SRL+CsA)
Number of subjects: 448
Study: 16319040

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (2 g IV Mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12599844

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1195
Study: 11764124

Group type: EXPERIMENTAL
Intervention: Gluma Comfort Bond/Solitaire II
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bond 1/Alert
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT/Surefil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: OptiBond Solo/Prodigy Condensable
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single Bond/Z250
Number of subjects: 40
Study: 8895675

Group type: EXPERIMENTAL
Intervention: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC) recirculated for one hour
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC)
Number of subjects: 9
Study: 1992381

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6220895

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg acute; 20 mg q.i.d. for 1 month)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Verapamil (160 mg acute; 160 mg t.i.d. for 1 month)
Number of subjects: 23
Study: 30824336

Group type: EXPERIMENTAL
Intervention: DMET (1 mg/kg delivered over 10 minutes at the time of surgical closure)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29808039

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A followed by task-specific training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Task-specific training
Number of subjects: 43
Study: 26786748

Group type: EXPERIMENTAL
Intervention: Overweight/obese children (BMI >85th percentile)
Number of subjects: 530
Study: 25424409

Group type: EXPERIMENTAL
Intervention: Dozier's Attachment and Biobehavioral Catch-up (ABC) intervention, 10 home-based sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 21
Study: 22642231

Group type: EXPERIMENTAL
Intervention: Guided Relaxation and Imagery (GRI)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Guided Relaxation with Music of Choice (Control)
Number of subjects: 91
Study: 20694277

Group type: EXPERIMENTAL
Intervention: Enoxaparin (prophylactic daily dose starting from positive pregnancy test)
Number of subjects: 160
Study: 18319369

Group type: EXPERIMENTAL
Intervention: Learning yogic breathing techniques alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning yogic breathing techniques combined with giving testimony
Number of subjects: 0
Study: 15750869

Group type: EXPERIMENTAL
Intervention: Simple stop signal task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective stop signal task
Number of subjects: 0
Study: 12427108

Group type: EXPERIMENTAL
Intervention: Watercress ingestion 1 hour before ethanol consumption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Watercress ingestion 10.5 hours before ethanol consumption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Watercress ingestion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Watercress ingestion immediately preceding ethanol consumption
Number of subjects: 9
Study: 10977833

Group type: EXPERIMENTAL
Intervention: Community postnatal support worker visits (up to 10 home visits in the first postnatal month, up to three hours duration each)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Community postnatal support worker visits
Number of subjects: 623

Group type: COMPARATOR
Intervention: Control group (usual care provided by community midwives)
Number of subjects: 623
Study: 9003961

Group type: EXPERIMENTAL
Intervention: Active treatment (transcranial electrostimulation)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study: 1611118

Group type: EXPERIMENTAL
Intervention: Intravesical interferon-alpha 2b
Number of subjects: 0
Study: 6735252

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg sustained release capsules taken 12 and 24 hours before, and 50 mg taken one hour before histamine infusion)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Matching placebo capsules
Number of subjects: 7
Study: 29349832

Group type: EXPERIMENTAL
Intervention: Bikram yoga practised at 40.5°C (n=19)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bikram yoga practised at 23°C (n=14)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sedentary time control (n=19)
Number of subjects: 52
Study: 26453910

Group type: EXPERIMENTAL
Intervention: Help4Mood
Number of subjects: 27

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Help4Mood (regular use)
Number of subjects: 27
Study: 25387282

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy (LPV/r-MT) 400/100 mg BID
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard of care (cART)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy (LPV/r-MT)
Number of subjects: 94
Study: 22494451

Group type: EXPERIMENTAL
Intervention: Robotic catheter ablation (ROB)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Manual catheter ablation (MAN)
Number of subjects: 303
Study: 20211038

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Both fish oil and folate
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 18806027

Group type: EXPERIMENTAL
Intervention: Chinese QoR score
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: English QoR score
Number of subjects: 210
Study: 15701892

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 330

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 330

Group type: COMPARATOR
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 330
Study: 12500989

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (60 g daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Whey protein (60 g daily)
Number of subjects: 35
Study: 11966624

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 30 MU
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 50 MU
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 80 MU
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mitomycin-C (40 mg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (all doses)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mitomycin-C
Number of subjects: 115
Study: 9661606

Group type: EXPERIMENTAL
Intervention: Nal‐Glu GnRH antagonist (5, 15, 50, and 150 micrograms/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nal‐Glu GnRH antagonist (150 micrograms/kg for 3-7 days)
Number of subjects: 11
Study: 7514520

Group type: EXPERIMENTAL
Intervention: Dansyl chloride labelling with surfactants and soap extracts (2% active ingredient, w/v)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactants and body cleansing products
Number of subjects: 0
Study: 2622549

Group type: EXPERIMENTAL
Intervention: Hill's modified technique
Number of subjects: 132

Group type: COMPARATOR
Intervention: Dor technique
Number of subjects: 132
Study: 329940

Group type: EXPERIMENTAL
Intervention: Layered closure with retention sutures
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single-layer 'mass closure'
Number of subjects: 200
Study: 6173843

Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30922358

Group type: EXPERIMENTAL
Intervention: Intervention territories created using territory design software
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control territories created using territory design software
Number of subjects: 24
Study: 29554849

Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Dose-equivalent usual occupational therapy (DEUCC)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Usual therapy (UCC)
Number of subjects: 361

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 361
Study: 27774458

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 18

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 18
Study: 24787632

Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program for COPD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of COPD patients not participating in the rehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 22486843

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 24
Study: 20528593

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP; 400 microg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP; 400 microg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 37
Study: 18413638

Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD) + RT
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Short-term ADT (STAD) + RT
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Long-term ADT (LTAD) + RT (Gleason score 8-10)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Short-term ADT (STAD) + RT (Gleason score 8-10)
Number of subjects: 1554
Study: 15786853

Group type: EXPERIMENTAL
Intervention: Exposed enrollees taking potentially contraindicated medications
Number of subjects: 406

Group type: COMPARATOR
Intervention: Unexposed enrollees not taking potentially contraindicated medications
Number of subjects: 406
Study: 14614228

Group type: EXPERIMENTAL
Intervention: Flutamide treatment for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 10673870

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Propofol and Sevoflurane
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 211
Study: 9552519

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 516

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 516
Study: 1987737

Group type: EXPERIMENTAL
Intervention: Epirubicin (Epi) 20 mg/m2 i.v. weekly
Number of subjects: 49

Group type: COMPARATOR
Intervention: Doxorubicin (Dox) 20 mg/m2 i.v. weekly
Number of subjects: 49
Study: 6307941

Group type: EXPERIMENTAL
Intervention: Prophylactic chemotherapy (cyclophosphamide and CCNU)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Delayed chemotherapy (cyclophosphamide and CCNU)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Thoracic irradiation (TI), brain irradiation (BI), and early chemotherapy (CT)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Thoracic irradiation (TI) alone
Number of subjects: 271

Group type: COMPARATOR
Intervention: Thoracic irradiation (TI) and chemotherapy (CT)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Thoracic irradiation (TI) and brain irradiation (BI)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Elective brain irradiation
Number of subjects: 271
Study: 31752566

Group type: EXPERIMENTAL
Intervention: Zal-SNEDDS
Number of subjects: 40
Study: 29504254

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol at 25,000 IU/wk
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27176725

Group type: EXPERIMENTAL
Intervention: Hydrogen water (1000 mL/day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo water (normal water)
Number of subjects: 178
Study: 24524674

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling intervention
Number of subjects: 728

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 728
Study: 22101215

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment
Number of subjects: 30
Study: 20622677

Group type: EXPERIMENTAL
Intervention: CD4 < or =50/VL >100,000
Number of subjects: 2948

Group type: EXPERIMENTAL
Intervention: CD4 < or =50/VL < or =100,000
Number of subjects: 2948

Group type: EXPERIMENTAL
Intervention: CD4 51-200/VL >100,000
Number of subjects: 2948

Group type: EXPERIMENTAL
Intervention: CD4 51-200/VL < or =100,000
Number of subjects: 2948
Study: 17663611

Group type: EXPERIMENTAL
Intervention: Family-centered intervention (Family Check-Up)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Control group (randomized matched controls)
Number of subjects: 998
Study: 15642301

Group type: EXPERIMENTAL
Intervention: 'J' wire
Number of subjects: 50

Group type: COMPARATOR
Intervention: Straight wire
Number of subjects: 50
Study: 12271348

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (LP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etch&Prime 3.0 (EP)
Number of subjects: 90
Study: 10598708

Group type: EXPERIMENTAL
Intervention: Codman Hakim programmable shunt valve
Number of subjects: 377

Group type: COMPARATOR
Intervention: Conventional valve system
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 377
Study: 9163011

Group type: EXPERIMENTAL
Intervention: Cisplatin administered in the evening (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cisplatin administered in the morning (Group B)
Number of subjects: 80
Study: 1937374

Group type: EXPERIMENTAL
Intervention: 2 x 400 mg cimetidine daily for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2 x 400 mg cimetidine daily for 28 days
Number of subjects: 100
Study: 7023678

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 gm/day initially, increased to 1.6 gm/day for those with less than 50% reduction in ulcer size after three weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (one tablet after lunch and one at bedtime)
Number of subjects: 20
Study: 29268619

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide/dexamethasone (Pom/dex)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Pomalidomide/dexamethasone (Pom/dex) alone
Number of subjects: 300
Study: 27355267

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Insulin (standard of care)
Number of subjects: 44
Study: 23798044

Group type: EXPERIMENTAL
Intervention: Walking VO(2max) test
Number of subjects: 12

Group type: COMPARATOR
Intervention: Running VO(2max) test
Number of subjects: 12
Study: 21126782

Group type: EXPERIMENTAL
Intervention: Flat panel digital detector (FPDD) fluoroscopy
Number of subjects: 400
Study: 20308671

Group type: EXPERIMENTAL
Intervention: EC plus docetaxel
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: EC plus TX (docetaxel + capecitabine)
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: EC plus T-X (docetaxel followed by capecitabine)
Number of subjects: 1421

Group type: COMPARATOR
Intervention: EC plus TX
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: EC plus T-X
Number of subjects: 1421
Study: 18535027

Group type: EXPERIMENTAL
Intervention: Individualised rehabilitation programme (treatment group, n = 49)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control waitlist group (n = 52)
Number of subjects: 101
Study: 15992459

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 3 weeks)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 12460864

Group type: EXPERIMENTAL
Intervention: Plasma Urotensin II (UTN) levels in heart failure patients
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Plasma N-terminal pro-brain natriuretic peptide (N-BNP) levels in heart failure patients
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for diagnosis of HF using N-BNP
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for diagnosis of HF using UTN
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for diagnosis of NYHA class I HF using UTN
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 126
Study: 10731304

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg) given 30 min or 3.5 hours before exertion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chronic treatment with Nedocromil sodium for 2 and 4 weeks
Number of subjects: 18
Study: 7594444

Group type: EXPERIMENTAL
Intervention: Sinorphan (100 mg twice a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined therapy of Sinorphan and Captopril
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sinorphan alone or in combination with Captopril
Number of subjects: 16
Study: 1940778

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation programme
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 305
Study: 7272867

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (one 4-I plasma exchange a month)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional therapy only (Control)
Number of subjects: 12
Study: 31990296

Group type: EXPERIMENTAL
Intervention: Vitamin C infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30099756

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar puncture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Landmark-based lumbar puncture
Number of subjects: 35
Study: 27719107

Group type: EXPERIMENTAL
Intervention: Playing form activity through the PLUNGE into Sport programme (9 training sessions of 30 min each)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 9-week wait-list control
Number of subjects: 90
Study: 26332592

Group type: EXPERIMENTAL
Intervention: eHealth intervention (interactive website)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1150
Study: 23453391

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU once weekly for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21425568

Group type: EXPERIMENTAL
Intervention: Composite Sophora Colon‐soluble Capsules (CSCC) plus Etiasa simulated placebo for 8 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Etiasa plus CSCC simulated placebo for 8 weeks
Number of subjects: 160
Study: 19251139

Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microcoaxial phacoemulsification (microphaco)
Number of subjects: 0
Study: 16882940

Group type: EXPERIMENTAL
Intervention: Topotecan (TC-Top) following carboplatin and paclitaxel
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Surveillance (TC) following carboplatin and paclitaxel
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Topotecan (TC-Top)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Surveillance (TC)
Number of subjects: 1308
Study: 15554364

Group type: EXPERIMENTAL
Intervention: Type I diabetes patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy sedentary males
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups with BMI above 25 kg/m2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups with BMI below 25 kg/m2
Number of subjects: 27
Study: 11730742

Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg once daily)
Number of subjects: 201

Group type: COMPARATOR
Intervention: IM progesterone (50 mg once daily)
Number of subjects: 201
Study: 9164992

Group type: EXPERIMENTAL
Intervention: Acarbose (50-200 mg, three times per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 0
Study: 8083699

Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg) capsules taken for 4 days before and 2 days after chemotherapy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 2769131

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Iodophor cream
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chlorhexidine cream
Number of subjects: 150
Study: 239807

Group type: EXPERIMENTAL
Intervention: Lorazepam 1.33 mg intramuscularly
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg intramuscularly
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pentobarbital 50 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pentobarbital 150 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pentazocine 30 mg intramuscularly
Number of subjects: 3